Coherus BioSciences, Inc.
CHRS
$0.7818
-$0.0349-4.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.78% | 44.19% | 69.37% | 64.63% | 21.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.78% | 44.19% | 69.37% | 64.63% | 21.89% |
| Cost of Revenue | -26.06% | 89.85% | 97.71% | 127.75% | 126.86% |
| Gross Profit | 52.07% | 11.13% | 40.92% | 18.33% | -30.30% |
| SG&A Expenses | -18.20% | -13.96% | -7.84% | -5.63% | -7.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.48% | 9.19% | 9.89% | 8.90% | -4.10% |
| Operating Income | 50.72% | 31.94% | 37.02% | 33.66% | 25.45% |
| Income Before Tax | 111.96% | 99.79% | 88.75% | 78.01% | 18.33% |
| Income Tax Expenses | -- | 100.00% | -- | -- | -- |
| Earnings from Continuing Operations | 111.98% | 99.79% | 88.89% | 78.15% | 18.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.98% | 99.79% | 88.89% | 78.15% | 18.46% |
| EBIT | 50.72% | 31.94% | 37.02% | 33.66% | 25.45% |
| EBITDA | 52.54% | 33.50% | 38.00% | 34.41% | 25.86% |
| EPS Basic | 110.42% | 99.70% | 90.35% | 79.87% | 31.74% |
| Normalized Basic EPS | 3.50% | 56.00% | 56.99% | 44.68% | 33.44% |
| EPS Diluted | 105.99% | 96.32% | 87.56% | 77.25% | 31.43% |
| Normalized Diluted EPS | 4.98% | 57.43% | 58.10% | 45.74% | 33.44% |
| Average Basic Shares Outstanding | 21.94% | 32.74% | 35.55% | 30.95% | 21.02% |
| Average Diluted Shares Outstanding | 25.34% | 36.47% | 39.52% | 35.04% | 21.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
